Phase II Image Guided Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer
Stopped early · Not applicable
Conditions studied: Non Small Cell Lung Cancer
In brief
This study will help researchers learn about the best dose of radiation to be used when treating large early stage non-small cell lung cancer (NSCLC) with a treatment called stereotactic ablative radiotherapy (SABR). Current treatments with SABR for early stage NSCLC show positive response. But, for large early stage NSCLC it may be better to give different SABR doses than what is used in routine early stage NSCLC treatment. It is not understood which dose is best for treating large early stage NSCLC. Therefore, this study can help researchers learn if giving a higher dose using SABR over a period of 5-10 treatment days can increase the chance of cure for large early stage NSCLC.
Key facts
- Study ID
- NCT02262000
- Run by
- West Virginia University
- People needed
- 3
- Starts
- 2013-09-01
- Expected to finish
- 2017-07-10
- Last updated by the study team
- 2021-01-22
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Non-Small Cell Lung Cancer
- T2N0M0 or T3(PL3)N0M0 or Locally recurrent ≤ 7 cm
- Surgically inoperable
- ECOG Performance 0-2
You may not qualify if…
- Pacemaker on the same side of the tumor
- Pregnant
- Infection that requires IV antibiotics
- Concomitant or adjuvant anti-neoplastic chemotherapy
Where it is running
- West Virginia University Hospitals Mary Babb Randolph Cancer Center — Morgantown, West Virginia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.